Latest Headlines

Latest Headlines

Unilife signs supply agreement for Depot-ject delivery system

Developer and supplier of drug delivery systems Unilife announced last week the signing of a worldwide, 10-year commercial supply agreement with a global pharmaceutical company for the use of its Depot-ject with an ocular injection therapy.

BoneSupport, Orthocell partner to develop a novel bone repair product

Australian regenerative medicine company Orthocell and Scandinavian med tech BoneSupport will work together to combine their existing products into a new bone repair product. The pair hopes to further tap into the global bone graft and substitutes market, which the companies said was $2.1 billion last year and is expected to be $2.7 billion by 2020.

Amgen and Merck kick off a combo cancer trial

Amgen and Merck have launched an early-stage trial pairing their respective cancer immunotherapies, looking to confirm the clinical and commercial promise of combination approaches to cancer.

Pfizer strikes another immunotherapy deal to widen its oncology pipeline

With its designs on AstraZeneca at least temporarily abandoned, Pfizer has set out to create an immuno-oncology portfolio of its own, signing a deal with a Belgian biotech to get its hands on treatments that promise to sharpen the body's anticancer weaponry.

Pfizer buys into gene therapy's renaissance and bets on Spark Therapeutics

Pfizer is the latest pharma heavyweight to get behind the promise of gene therapy, as the New York drugmaker has laid out plans to set up a dedicated R&D operation and signed a deal with startup Spark Therapeutics to kick-start the effort.

BlackBerry, NantHealth to launch HIPAA secure smartphone genome browser

BlackBerry, maker of the Passport smartphone, and health analytics company NantHealth said they will launch a clinical genome browser early next year that will be HIPAA-compliant.

INC Research lends its weight to trial site advocacy group

INC Research has deepened its partnership with the Society for Clinical Research Sites, supporting a training program and working to increase communication between trial sites and study investigators.

Catalent signs on to help Sellas get a repurposed drug to the finish line

Catalent has signed a deal with Sellas to help the Swiss drugmaker develop an existing insomnia treatment for other central nervous system disorders.

Recipharm cues job cuts as a long-time partner drops out

Meda, a Swedish specialty pharma outfit, is scaling back its relationship with contract drug developer Recipharm, endangering jobs and putting a site at risk of closure.

Welch Allyn partners with LKC to distribute novel diabetic retinopathy device

Point-of-care diagnostics company Welch Allyn and visual electrophysiology player LKC Technologies have signed an exclusive partnership for the former to distribute the latter's RETeval DR device, which screens for diabetic retinopathy.